sintilimab + ifosfamide + carboplatin + etoposide

This is a **combination regimen** consisting of **sintilimab** (a PD-1 inhibitor/monoclonal antibody against programmed cell death protein 1), **ifosfamide** (an alkylating agent), **carboplatin** (a platinum-based chemotherapy), and **etoposide** (a topoisomerase II inhibitor). Sintilimab is an immune checkpoint inhibitor that blocks PD-1, enhancing T-cell mediated anti-tumor immune responses. The addition of sintilimab to the ICE chemotherapy regimen (ifosfamide, carboplatin, etoposide) has shown improved complete remission rates and favorable progression-free survival in patients with **relapsed or refractory classical Hodgkin lymphoma** who have failed first-line chemotherapy. The regimen was studied in a multicenter, randomized, double-blind phase 3 trial (the ORIENT-21 study) and is not approved by the US FDA; conditional approval for sintilimab monotherapy exists in China for third-line cHL. The regimen has an acceptable safety profile, with hematologic toxicities as the main adverse events[1][5][6][8].

Other names

sintilimab plus ICE